<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://www.medscape.com/cx/rssfeeds/2700.xml</title><link>https://www.medscape.com/cx/rssfeeds/2700.xml</link><description>Individual feed output.</description><lastBuildDate>Mon, 22 Sep 2025 17:20:54 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Can ctDNA Guide Immunotherapy in Limited-Stage SCLC?</title><link>https://www.medscape.com/viewarticle/can-ctdna-guide-immunotherapy-limited-stage-sclc-2025a1000p84?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture4.png</image_url><description>Monitoring ctDNA may help identify patients with limited-stage small cell lung cancer who are likely to benefit from consolidation immunotherapy and t...</description><pubDate>Mon, 22 Sep 2025 21:03:36 GMT</pubDate></item><item><title>Severe Obesity Linked to Lower Cancer Screening Rates</title><link>https://www.medscape.com/viewarticle/severe-obesity-linked-lower-cancer-screening-rates-2025a1000p82?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture2.png</image_url><description>Adults with severe obesity are less likely to undergo cancer screening, particularly colonoscopy and prostate-specific antigen testing, than those wit...</description><pubDate>Mon, 22 Sep 2025 20:34:00 GMT</pubDate></item><item><title>Phase 3 Data Put Povorcitinib on HS Radar</title><link>https://www.medscape.com/viewarticle/phase-3-data-put-povorcitinib-hs-radar-2025a1000p7u?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture1.png</image_url><description>Interim STOP-HS1/2 data show povorcitinib yielded modest lesion reductions, improved pain scores, and some higher-threshold clinical responses in pati...</description><pubDate>Mon, 22 Sep 2025 19:22:11 GMT</pubDate></item><item><title>EMA Backs First FcRn Inhibitor for Myasthenia Gravis</title><link>https://www.medscape.com/viewarticle/ema-backs-first-fcrn-inhibitor-myasthenia-gravis-2025a1000p7b?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png</image_url><description>In clinical trials, Imaavy plus standard therapy improved muscle strength and daily function in adults and adolescents with generalized myasthenia gra...</description><pubDate>Mon, 22 Sep 2025 16:29:06 GMT</pubDate></item><item><title>Biosimilar for Inflammatory Diseases Clears EU Hurdle</title><link>https://www.medscape.com/viewarticle/biosimilar-inflammatory-diseases-clears-eu-hurdle-2025a1000p7a?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture1.png</image_url><description>The EMAâ€™s recommendation marks a key step toward expanding treatment access for patients with psoriasis, psoriatic arthritis, and inflammatory bowel d...</description><pubDate>Mon, 22 Sep 2025 16:10:16 GMT</pubDate></item></channel></rss>